Dishman Carbogen Amcis Gears Up for Q3 Reveal on 3rd February; Check Key Expectations Here

Dishman Carbogen Amcis's Q3 results FY26 are scheduled to be announced on 3rd February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Dishman Carbogen Amcis Q3 Results 2026 Preview

• Dishman Carbogen Amcis' revenue is expected to be in the range of ₹682.34 crore, a 13.52% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise by 86.01% YoY. 
• Net profit is ₹4.63 crore, a fall 86.01% YoY 
• EBITDA to rise 2.64%

Dishman Carbogen Amcis Share Performance 

• Over the past six months, Dishman Carbogen Amcis's share price has fallen by 86.01% to ₹4.63.
• Moreover, over the past year, the stock has decreased by 30.49%.
• Despite this weak short-term performance, Dishman Carbogen Amcis's stock has delivered a financially sound 479.67% return over the past 5 years.
• As of 3rd February 2026, the stock traded at ₹870.95 per share.

Key Factors to Watch for Dishman Carbogen Amcis Q3 Results FY26 

1. Revenue & Segment Growth: Look at overall sales and growth in key segments like CRAMS (Contract Research, Development & Manufacturing) and marketable molecules — strong demand or new contracts can boost top line.
   
2. Profitability & Margins: EBITDA and net profit margins will show how efficiently the company is converting revenue into earnings, especially after recent turnaround trends.
   
3. Order Book & New Contracts: Any updates on large contract wins or expansion of long‑term deals, including those in high‑growth areas like oncology and ADC linkers.
   
4. Capacity Utilisation & Regulatory Approvals: Progress on new facility ramp‑ups (France GMP and Swiss ADC capacity) and regulatory certifications that enable higher production.
   
5. Cost & Cash Flow Trends: Trends in operating costs, net debt levels, and cash flow from operations, as these affect financial strength and ability to fund growth.
   

Final Thoughts

Dishman Carbogen Amcis will announce its Q3 FY26 results on 2nd February 2026. Analysts expect 15.65% YoY revenue growth, a 17.81% rise in PAT, and a 25.75% rise in EBITDA. Dishman Carbogen Amcis focuses on contract research, development & manufacturing (CRAMS), specialty molecules, oncology & ADC-related products, capacity expansion, and strengthening global client partnerships.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here

Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here